Biocon launches long acting insulin substitute

Biocon Limited, India's second largest bio-technology firm, has announced the launch of Basalog, a human insulin analogue, which attempts to relieve diabetic patients of frequent insulin shots in a day.

According to Biocon, this new product is effective for 24 hours.

The company which is primarily focussing on finding diabetes and cancer care drugs, is parallely working on oral insulin which will further alleviate the trauma of diabetic patients having to take frequent injections of insulin substitute.

The new offering while being effective for 24 hours will also help in  avoiding low blood sugar, and better glucose control in the body.